Phase III CIDS trial demonstrates NexoBrid's effectiveness in pediatric burn patients, achieving complete eschar removal in one day compared to six days with standard care.
Mediwound has been given a Buy rating by Michael Okunewitch of Maxim Group, driven by the promising market potential of its product EscharEx in chronic wound care, with a price target of $30.00.
MediWound has commenced a Phase II clinical trial to assess EscharEx for treating venous leg ulcers, with results expected to support a BLA submission.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.